IP Verse

Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells

Patent No. EP3377103 (titled "Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells") was filed by Revitope on Nov 18, 2016. The application was issued on Mar 12, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TAKEDA PHARMACEUTICALDec 17, 2021DOLPHIN
CHERRY BIOLABSDec 16, 2021MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3377103

REVITOPE
Application Number
EP16867215A
Filing Date
Nov 18, 2016
Status
Patent Maintained As Amended
Feb 7, 2025
Publication Date
Mar 12, 2025
External Links
Slate, Register , Google Patents